周奇

研究方向：肝膽胰脾臨床和基礎(chǔ)研究。 主要教育和工作經(jīng)歷： 學(xué)習(xí)經(jīng)歷：2001年9月-2004年6月: 中山大學(xué)外科學(xué)專業(yè)就讀，獲得博士學(xué)位。 工作經(jīng)歷：2004年7月-至今：中山大學(xué)附屬第一醫(yī)院肝膽外科主治醫(yī)師、副主任醫(yī)師、主任醫(yī)師 社會(huì)兼職： 中國(guó)醫(yī)藥教育協(xié)會(huì)醫(yī)療裝備工作委員會(huì)副主任委員；廣東省健康管理學(xué)會(huì)肝膽胰微創(chuàng)專委會(huì)主任委員；廣東省醫(yī)學(xué)會(huì)肝膽胰外科學(xué)分會(huì)術(shù)中輔助診斷學(xué)組組長(zhǎng)；廣東省醫(yī)師協(xié)會(huì)肝癌學(xué)組副組長(zhǎng)。 論著： 1、Obg-like ATPase 1 (OLA1) overexpression predicts poor prognosis and promotes tumor progression by regulating P21/CDK2 in hepatocellular Carcinoma《AGING》2020 2、Bioinformatics analysis on multiple Gene Expression Omnibus datasets of the hepatitis B virus infection and its response to the interferon-alpha therapy《BMC Infectious Diseases》2020 3、Uridine-cytidine kinase 2 upregulation predicts poor prognosis of hepatocellular carcinoma and is associated with cancer aggressiveness.《Molecular Carcinogenesis》 2019 4、Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma.《Journal of Experimental & Clinical Cancer Research》2019 5、Comprehensive and combined omics analysis reveals factors of ischemia-reperfusion injury in liver transplantation. 《Epigenomics》 2019 6、Targeting TF-AKT/EGFR Pathway Suppressed the Growth Of Hepatocellular Carcinoma. 《Frontiers in Oncology》 2019 7、A comprehensive bioinformatics analysis on multiple Gene Expression Omnibus datasets of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. 《Sci Rep》 2018 8、Overexpression of signal sequence receptor γ (SSR3) predicts poor survival in patients with hepatocellular carcinoma.《Hum Pathol》 2018 9、Formylpeptide receptor 1 mediates the tumorigenicity of human hepatocellular carcinoma cells.《OncoImmunology》 2016 10、High expression of hexokinase domain containing 1 is associated with poor prognosis and aggressive phenotype in hepatocarcinoma.《Biochemical and Biophysical Research Communications》 2016 11、Adult hepatic cavernous hemangioma with highly elevated α?fetoprotein: A case report and review of the literature.《Oncol Lett》 2015 12、Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon al...

主治原發(fā)性肝癌、膽囊癌、膽管癌、胰腺癌、肝血管瘤、門脈高壓、上消化道出血、肝內(nèi)外膽管結(jié)石等良惡性疾病。擅長(zhǎng)膽囊癌根治術(shù);肝門部膽管癌根治術(shù);復(fù)雜膽道結(jié)石手術(shù);胰頭、體尾癌根治術(shù);微創(chuàng)肝切除、膽囊切除,肝癌射頻消融術(shù)等。對(duì)原發(fā)性肝癌侵襲轉(zhuǎn)移治療有豐富經(jīng)驗(yàn)。